Incurred sample reanalysis [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-04-10 10:40 (4828 d 15:53 ago) – Posting: # 10387
Views: 17,533

Dear Ohlbe,

❝ The long-term stability is not the only issue anyway: back-conversion during sample processing can be of greater concern. And are you sure you know all metabolites ? EMA got trapped in their recommendations on clopidogrel1


I just happened to be cruising by this joint looking for anything new on ISR. Glad to see you tapping this subject. You answered a lot of my questions, except I'm not sure I understand what you mean by the EMA getting trapped. Do you mean that there are ways around justifying clopidogrel, or other drugs known for back-conversion, that EMA hadn't considered (the paper you quoted where the authors found a way of controlling back-conversion)? Is that it? If that's not the case, mind expanding on this while I sit back and have a drink?

Thanks,
Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
308 visitors (0 registered, 308 guests [including 45 identified bots]).
Forum time: 02:33 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5